Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 5/20 | 0.55 |
| ▸ | CXCR1 | P25024 | 5/20 | 0.55 |
| ▸ | CXCL8 | P10145 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | TTR | P02766 | 2/20 | 0.51 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.49 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.49 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.49 |
| ▸ | ALB | P02768 | 1/20 | 0.49 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7167408 | 0.90 | CXCR2 (0.57) | CXCR2CXCR1CXCL8MEN1KMT2A | |
| SCHEMBL7165961 | 0.84 | CXCL8 (0.64) | CXCL8MEN1KMT2AMAPTCYP1A2 | |
| SCHEMBL7164914 | 0.83 | GAA (0.64) | MEN1KMT2AMAPTCYP1A2KCNMA1 | |
| SCHEMBL7165547 | 0.81 | L3MBTL1 (0.57) | CXCR2CXCR1CXCL8MEN1KMT2A | |
| SCHEMBL7161755 | 0.81 | MEN1 (0.58) | MEN1KMT2AMAPTCYP1A2KCNMA1 | |
| SCHEMBL7169174 | 0.81 | ALDH1A1 (0.56) | CXCR1CXCL8MEN1KMT2AMAPT | |
| SCHEMBL7166087 | 0.80 | CXCL8 (0.51) | CXCR1CXCL8MAPTCYP1A2TTR | |
| SCHEMBL7160777 | 0.80 | CAMK2A (0.55) | CXCR1CXCL8MEN1KMT2AMAPT | |
| SCHEMBL7165423 | 0.79 | CXCL8 (0.68) | CXCR2CXCR1CXCL8TTRCYP2C9 | |
| SCHEMBL6037267 | 0.79 | CYP1A2 (0.73) | CXCR2CXCR1MAPTTDP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6552077-B2 | Kidney disorders | EXOCELL, INC. | 2003-04-22 | — | — | US | disclosed |
| EP-1242069-A2 | ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES | EXOCELL, INC. (US) | 2002-09-25 | — | — | EP | disclosed |
| US-6355680-B1 | BLOCKING REACTION OF GLUCOSE AND ALBUMIN | EXOCELL, INC. | 2002-03-12 | — | — | US | disclosed |
| US-20010034359-A1 | Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies | EXOCELL, INC. | 2001-10-25 | — | — | US | disclosed |
| WO-2001003684-A2 | ALBUMIN-BINDING COMPOUNDS THAT PREVENT NONENZYMATIC GLYCATION AND THAT MAY BE USED FOR TREATMENT OF GLYCATION-RELATED PATHOLOGIES | EXOCELL, INC. (US) | 2001-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034359-A1 | Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies | ALB, AGER, TTR | CXCR2 4689/4885CXCR1 4283/4885CXCL8 3032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.